Literature DB >> 1810958

High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine.

I Aoki1, M Okumura, T Yashiki.   

Abstract

A simple and sensitive high-performance liquid chromatographic method with ultraviolet detection is described for the simultaneous determination of lansoprazole and its metabolites in human serum and urine. The analytes in serum or urine were extracted with diethyl ether-dichloromethane (7:3, v/v) followed by evaporation, dissolution and injection into a reversed-phase column. The recoveries of authentic analytes added to serum at 0.05-2 micrograms/ml or to urine at 1-20 micrograms/ml were greater than 88%, with the coefficients of variation less than 7.1%. The minimum determinable concentrations of all analytes were 5 ng/ml in serum and 50 ng/ml in urine. The method was successfully applied to a pharmacokinetic study of lansoprazole in human.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810958     DOI: 10.1016/0378-4347(91)80457-n

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Authors:  T Sakai; N Aoyama; T Kita; T Sakaeda; K Nishiguchi; Y Nishitora; T Hohda; D Sirasaka; T Tamura; Y Tanigawara; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.

Authors:  H Katsuki; H Yagi; K Arimori; C Nakamura; M Nakano; S Katafuchi; Y Fujioka; S Fujiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

4.  Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC.

Authors:  A Avgerinos; T h Karidas; C Potsides; S Axarlis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 5.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

6.  Determination of omeprazole in rat plasma by HPLC with column switching.

Authors:  S H Shim; S J Bok; K I Kwon
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

Review 7.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

8.  Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

Authors:  V Shakhnovich; S Abdel-Rahman; C A Friesen; J Weigel; R E Pearce; A Gaedigk; J S Leeder; G L Kearns
Journal:  Pediatr Obes       Date:  2018-09-26       Impact factor: 4.000

9.  Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum.

Authors:  K Nagata; E Takagi; H Satoh; H Okamura; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

10.  Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.

Authors:  Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich
Journal:  Clin Transl Sci       Date:  2022-02-14       Impact factor: 4.438

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.